Materials and methods
Clinical effectiveness and Qol were assessed using the Clinical Global Impression (CGI) scale and the EQ-5D instrument, respectively. For analysis, the 2-year period was split into four 6-month epochs (0-6, 6-12, 12-18 and 18-24 months) . Multivariate modelling was performed, adjusting for baseline differences among patients.
Results
Olanzapine-treated patients had statistically higher overall CGI improvements during i) the first 6 months, compared with risperidone (0.20; 0.14-0.26), quetiapine (0.24; 0.15-0.33), amisulpride (0.12; 0.00-0.23), oral (0.33; 0.25-0.41) and depot typicals (0.33; 0.24-0.42) treated patients, and ii) second 6 months compared with oral typicals (0.12; 0.04-0.19) treated patients. No statistical separation was observed between the olanzapine and clozapine groups.
Olanzapine-treated patients had statistically higher EQ-5D utility improvements during the first 6 months compared with risperidone (0.034; 0.015-0. 
Discussion
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